The US FDA has approved CSL's HEMGENIX (etranacogene dezaparvovec-drlb) as the first and only one-time gene therapy for appropriate adults with haemophilia B.
CSL secures US approval for breakthrough one-time haemophilia gene therapy
November 24, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
HBF reports revenue growth with expanding membership outside WA
September 25, 2023 - - Other Health -
US FDA grants conditional approval to the brand name of Dimerix's DMX-200
September 25, 2023 - - Australian Biotech -
Budget outcome confirms double-digit growth for pharmaceutical spend
September 25, 2023 - - Latest News -
These major processes related to public health programs can not continue in this way
September 25, 2023 - - Latest News -
Hospital pharmacy launches new professional recognition program
September 25, 2023 - - Latest News -
The 'Week in Review' Podcast - 22 September
September 22, 2023 - - Podcast -
National and Labour commit to addressing Pharmac's fiscal 'cliff'
September 22, 2023 - - Latest News